Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675250 | 0.88 | GCK (0.43) | GCKAKR1C3AKR1C2GRM4 | |
| SCHEMBL2675248 | 0.88 | GCK (0.43) | GCKAKR1C3AKR1C2GRM4 | |
| SCHEMBL2675285 | 0.88 | GCK (0.43) | GCKAKR1C3AKR1C2GRM4 | |
| SCHEMBL1107743 | 0.84 | GCK (0.45) | GCKAKR1C3AKR1C2GRM4 | |
| SCHEMBL1865137 | 0.84 | GCK (0.58) | GCK | |
| SCHEMBL1865136 | 0.84 | GCK (0.58) | GCK | |
| SCHEMBL4263113 | 0.84 | GCK (0.45) | GCKAKR1C3AKR1C2GRM4 | |
| SCHEMBL2646180 | 0.83 | GCK (0.57) | GCK | |
| SCHEMBL2646260 | 0.83 | GCK (0.57) | GCK | |
| SCHEMBL15780423 | 0.83 | GCK (0.41) | GCKAKR1C3AKR1C2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281142-A1 | THIAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281142-A1 | THIAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281142-A1 | THIAZOLE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1921074-A1 | THIAZOLE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1921074-A1 | THIAZOLE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281142-A1 | THIAZOLE DERIVATIVE | GK, GCKR, AK2 | GCK 5/4885AKR1C3 481/4885AKR1C2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.